Patient-Oriented Evidence That Matters

Evidence of Benefit Is Lacking for Low Back Pain Relief With Muscle Relaxants


Am Fam Physician. 2022 Jan ;105(1):95-96.

Clinical Question

Do muscle relaxants provide relief for nonspecific lower back pain?

Bottom Line

Nonsteroidal anti-inflammatory drugs are a better choice for the treatment of low back pain. Despite benzodiazepine and nonbenzodiazepine muscle relaxants being used for almost 50 years to treat low back pain, the supporting evidence is of low certainty. None of the treatments will produce a clinically important difference over placebo. (Level of Evidence = 1a-)


The researchers searched eight databases, including the Cochrane Library, as well as conference abstracts and trial registries, identifying 49 trials (N = 6,505) that evaluated efficacy and acceptability. The authors included randomized clinical trials published in English, Italian, Portuguese, Spanish, German, and Dutch that compared a benzodiazepine or nonbenzodiazepine muscle relaxant with placebo, usual care, waiting list, or no treatment. In 16 trials, participants taking a nonbenzodiazepine muscle relaxant (n = 4,546) reported a pain intensity that was an average of 7.7 points lower (on a 100-point scale; 95% CI, 3.3 to 12.1) at two weeks than the average pain intensity reported by participants in a control group (a difference of less than 10 points is not clinically important). When examining only published studies, the difference in pain relief increased to an average of 10.2 points (95% CI, 4.7 to 15.6).

Analyzing studies with a low risk of bias or with a placebo control resulted in no difference in pain relief. In 22 trials that examined 3,404 patients for safety and tolerability, nonbenzodiazepine antispasmodics were more likely to cause an adverse event (relative risk = 1.6; 95% CI, 1.2 to 2.0) compared with control treatment, but were not less likely to be discontinued (relative risk = 1.5; 95% CI, 0.6 to 3.5). Antispasmodics and benzodiazepines produced no differences in pain intensity within two weeks or at weeks 3 through 13. There was significant heterogeneity among trial results for antispasmodics,

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP

Editor's Collections

Related Content

More in Pubmed


May 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article